Bristol-Myers Squibb Company (BMY) is set to announce its Q315 earnings Tuesday before the markets open. Analysts expect the developer of biopharmaceutical products to report EPS of $0.35 and revenue of $3.83 billion. That would be $0.18 lower the $0.53 per share posted last quarter, and $0.10 lower the $0.45 posted in the Q314. Revenue is projected to be $90 million lower than the $3.92 billion posted in the same period a year earlier. Meanwhile, EarningsWhisper.com reports a whisper number of $0.39 per share.
As a quick reminder, Bristol-Myers reported Q215 EPS of $0.53, $0.17 better than the Street’s consensus estimate of $0.36. Revenue increased 6.94% year-over-year to $4.16 billion vs. the $3.71 billion consensus.
On valuation measures, Bristol-Myers Squibb Co. shares have a T-12 price/sales ratio of 6.63 and a price/book for the same period of 7.18. EPS is $1.07. The name has a market cap of $108.65 billion and a median Wall Street price target of $74 with a high target of $80. Currently there are 13 analysts that rate BMY a ‘Buy’, 10 rate it a ‘Hold’. No analyst rates it a ‘Sell’.
In terms of share statistics, Bristol-Myers has a total of 1.67 billion shares outstanding with 0.13% held by insiders and 71.80% held by institutions. The stock’s short interest currently stands at 1.54%, bringing the total number of shares sold short to 25.65 million.
Offering a dividend yield of 2.27%, shares of the New York-based firm are up 27.11% year-over-year and 12.35% year-to-date.